not tagged
not tagged
['mds', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)']
#eha22 #mdssm wei: goal of therapy in lr-mds is improved qol, but in hr-mds is to progression to aml and prolong life. ipss-r intermediate risk represents 20% of mds pts and is group in which is may be difficult to decide to allograft or not. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)